Neola Medical Board

Neola Medical’s Board consists of five members elected at Neola Medical’s Annual General Meeting on May 21, 2025.

Märta Lewander Xu

Chairman of the Board since 2019, former CEO on a part-time basis and board member for Neola Medical 2016-2019.

Experience and education

Märta Lewander Xu has a doctorate in technology in physics, has a master’s degree in technical physics and a teaching degree in mathematics and physics. Märta was employed at Gasporox AB (publ) in 2010 as CTO and has been CEO of Gasporox AB (publ) since January 2015, which is listed on Nasdaq First North, a board member of BeammWave AB, Serstech AB, Xtree AB and Inscientia AB, as well as a deputy board member of CxTx AB and chairman of Lund Laser Center at Lund University.

Märta Lewander Xu is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

378,496​ shares (of which 134,210 in endowment insurance), 60,000 warrants issued within the framework of Incentive program 2021/2025B, 100,000 warrants issued within the framework of Incentive program 2023/2027B.

Tommy Hedberg

Board member since 2022.

Experience and education

Tommy Hedberg, born 1955, has a Chemical Engineering degree in chemical engineering as well as post-secondary studies in economics. He also completed basic medical training through LIF (The Research-Based Pharmaceutical Industry in Sweden) during his tenure at Janssen Pharma. Tommy has held several senior leadership roles at Atos Medical, where he served as CEO from 1998 to 2014 and as a board member from 2014 to 2016. Prior to his CEO role, he was responsible for marketing and sales at Atos Medical between 1990 and 1998. Before joining Atos, he spent nine years in sales and marketing at Janssen Pharma and three years at Medscand. Tommy currently serves as Chairman of the Board at Lindhe Xtend and Askis, and as a Board Member at Avidicare Holding and Chordate Medical.

Tommy Hedberg is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

384,616 shares, 300,000 warrants issued within the framework of Incentive program 2023/2027B.

Mattias Lundin

Board member since 2022.

Experience and education

Mattias Lundin, born 1968, has a degree in marketing economics from IHM Business School in Stockholm and has completed multiple international strategy and leadership programs within Sara Lee Corporation, the Getinge Group, and IMD Lausanne. Mattias currently serves as CEO of Decon Group and has previously held positions such as CEO of Lumito AB (publ), Vice President Global Sales at CellaVision AB (publ), and various senior roles within Arjo Group (formerly Getinge), most recently as Vice President Commercial for International Mature Markets.

Mattias Lundin is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

50,000 shares, 300,000 warrants issued within the framework of Incentive program 2023/2027B.

Urban Ottosson

Board member since 2021.

Experience and education

Urban Ottosson has a master’s degree in economics from Lund University and an Executive Diploma degree from KTH Executive School in Stockholm. He has worked as CFO since 1999 in several companies, including HEXPOL, Beijer Electronics, Höganäs Group, Öresundskraft and Lammhults Design Group. He is also a private investor in addition to his assignments. Former board member of Lendify AB and chairman of the board of Modity Energy Trading. He was CFO of Neola Medical 2020-2021. He is the CEO and board member of Predictus Asset Management AB.

Urban Ottosson is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

584,240 shares, 100,000 warrants issued within the framework of the Incentive program 2021/2025A, 300,000 warrants issued within the framework of Incentive program 2023/2027B.

Monica Alfaro Welling

Board member since 2024.

Experience and education

Monica Alfaro Welling holds a Bachelor’s degree in Biology and a Bachelor’s degree in Economics from the University of California, Irvine, USA, as well as a Master of Business Administration (Cand.Merc) from the University of Southern Denmark. Monica is currently the co-founder and Managing Director of the consultancy firm Atheln in Los Angeles. She has previously held positions including Sr. VP of Sales & Marketing at Hythiam (now Catasys), Senior Director of Global Strategic Marketing at Allergan (now Abbvie), and Head of the Global Growth Hormone Strategic Marketing Group at Novo Nordisk in Denmark. She is board member of Henlez ApS.

Monica Alfaro Welling is independent in relation to the company and its management, independent in relation to the company’s major shareholders.

Number of shares held in the company

0 shares.